surufatinib + gemcitabine + nab-paclitaxel

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital

Conditions

Pancreatic CancerPancreatic Cancer, Adult

Phase 2

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Active, not recruitingNCT05908747

Tianjin Medical University Cancer Institute and HospitalPancreatic Cancer

Start: 2023-05-31End: 2026-05-01Target: 29Updated: 2026-02-10

Phase 3

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Not yet recruitingNCT07436741

Tianjin Medical University Cancer Institute and HospitalPancreatic Cancer, Adult

Start: 2026-02-01End: 2030-03-01Target: 106Updated: 2026-02-27

Related Papers

A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.

Journal of Clinical Oncology2025-05-28